Assembly Biosciences, Inc. cash flow to debt ratio of -1.56K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Assembly Biosciences, Inc.'s free cash flow has increased -19.52% from $-51.15M last year to $-41.16M, signaling increasing performance

Assembly Biosciences, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Assembly Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.01 today, signaling strengthened financials

Assembly Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Assembly Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Assembly Biosciences, Inc.'s profit margin has increased (-93.63%) in the last year from -140.87% to -8.98%, signaling increasing performance

Assembly Biosciences, Inc.'s short-term assets of $254.55M exceed its short-term liabilities of $48.78M

Assembly Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Assembly Biosciences, Inc.'s return on equity of -4.21%, is lower than 15.00%, indicating bad performance

Assembly Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Assembly Biosciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Assembly Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Assembly Biosciences, Inc. has negative free cash flow, indicating cash burn

Assembly Biosciences, Inc.'s yearly earnings has increased -84.76% since last year from $-40.18M to $-6.12M, signaling increasing performance

Assembly Biosciences, Inc.'s yearly revenue has increased 153.52% since last year from $28.52M to $72.30M, signaling increasing performance

ROIC -6.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Assembly Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Assembly Biosciences, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Assembly Biosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Assembly Biosciences, Inc. has insufficient data to evaluate this check.

Assembly Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Assembly Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Assembly Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Assembly Biosciences, Inc. is overvalued relative to its fair value price of -229.91 based on Earnings Fair Value model

Assembly Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Assembly Biosciences, Inc. has a price-to-book ratio of 2.28x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Assembly Biosciences, Inc. has a price-to-sales ratio of 6.36x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue